EUVIMEDEUVIMED entdecken
Crossref

Significance of Pre‐ and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core‐Binding Factor Acute Myeloid Leukemia

Chika Tokuda iD, Makoto Iwasaki, Junya Kanda, Tadakazu Kondo, Yasuyuki Arai, Takayuki Ishikawa, Ryusuke Yamamoto, Kazunori Imada, Yuki Oku, Yasunori Ueda iD, Ryosuke Takatani, Akihito Yonezawa und 23 weitere

European Journal of Haematology · 2025

DOI: 10.1111/ejh.70024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2025. Verfasst von Chika Tokuda und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Neoplasm, Residual, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Core Binding Factors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development, KAKENHI, Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Polymerase chain reaction (PCR)‐based Minimal residual disease (MRD) detection is commonly used for core‐binding factor acute myeloid leukemia (CBF‐AML), but its interpretation in the context of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remains under discussion.

Method

Using Kyoto Stem Cell Transplantation Group registry data, we included 96 patients who underwent allo‐HSCT between 2000 and 2019 for CBF‐AML.

Results

To assess MRD, quantitative PCR with GAPDH control was most used. As for pretransplant MRD, 2‐year overall survival (OS) and relapse‐free survival (RFS) of the weak positive group (50–200 copy/μgRNA) were 66.5% and 67.2%, and these were as unfavorable as those of the strong positive group (> 200 copy/μgRNA, OS; 64.3%, RFS; 54.5%) compared to the negative group (OS; 100%, RFS; 93.3%). In contrast, as regards posttransplant MRD, 2‐year OS of patients with lower maximum MRD during approximately half a year post‐transplantation period (50–350 copy/μgRNA, 81.5%) was comparable to that of MRD‐negative patients (84.5%). In multivariate analysis, higher maximum MRD (> 350 copy/μgRNA) was a significant unfavorable factor toward OS (hazard ratio: 6.3, p = 0.002) compared to negative MRD.

Conclusions

The interpretation of posttransplant MRD positivity should be approached with caution, particularly in cases with low‐level positivity as it might diminish over time.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasm, ResidualLeukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationCore Binding FactorsHumansMaleFemaleMiddle AgedAdultYoung AdultAdolescentAgedPrognosisTreatment OutcomeTransplantation, HomologousRegistries

Stichwörter der Autor:innen

allogeneic hematopoietic stem cell transplantation (allo‐HSCT)core‐binding factor acute myeloid leukemia (CBF‐AML)minimal residual disease (MRD)

Substanzen

Core Binding Factors

Autor:innen und Institutionen

  • Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
  • Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
  • Department of Hematology, Kokura Memorial Hospital, Kitakyushu, Japan.
  • Department of Hematology, Shizuoka General Hospital, Shizuoka, Japan.

ORCID-Profile: Chika Tokuda, Yasunori Ueda, Noriyoshi Yoshinaga

Förderung

  • Japan Agency for Medical Research and Development
  • KAKENHI
  • Japan Society for the Promotion of Science

Zitieren

APA

Tokuda, C., Iwasaki, M., Kanda, J., Kondo, T., Arai, Y., Ishikawa, T., Yamamoto, R., Imada, K., Oku, Y., Ueda, Y., Takatani, R., Yonezawa, A., Iwai, F., Yago, K., Ikeda, T., Yoshitsugu, K., Kitano, T., Akasaka, T., Nohgawa, M., …, & Kyoto Stem Cell Transplantation Group (KSCTG) (2025). Significance of Pre‐ and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core‐Binding Factor Acute Myeloid Leukemia. European Journal of Haematology. https://doi.org/10.1111/ejh.70024

Vancouver

Tokuda C, Iwasaki M, Kanda J, Kondo T, Arai Y, Ishikawa T, et al. Significance of Pre‐ and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core‐Binding Factor Acute Myeloid Leukemia. European Journal of Haematology. 2025. doi:10.1111/ejh.70024

BibTeX
@article{Tokuda2025,
  author = {Tokuda, Chika and Iwasaki, Makoto and Kanda, Junya and Kondo, Tadakazu and Arai, Yasuyuki and Ishikawa, Takayuki and Yamamoto, Ryusuke and Imada, Kazunori and Oku, Yuki and Ueda, Yasunori and Takatani, Ryosuke and Yonezawa, Akihito and Iwai, Fumie and Yago, Kazuhiro and Ikeda, Takashi and Yoshitsugu, Kanako and Kitano, Toshiyuki and Akasaka, Takashi and Nohgawa, Masaharu and Tanaka, Yasuhiro and Itoh, Mitsuru and Takeoka, Tomoharu and Anzai, Naoyuki and Onda, Yoshiyuki and Arima, Nobuyoshi and Tsunemine, Hiroko and Hishizawa, Masakatsu and Watanabe, Mitsumasa and Hirata, Hirokazu and Asagoe, Kosuke and Yoshinaga, Noriyoshi and Sakamoto, Takashi and Yamashita, Kouhei and Takaori-Kondo, Akifumi and Kyoto Stem Cell Transplantation Group (KSCTG), Kyoto Stem Cell Transplantation Group (KSCTG)},
  title = {Significance of Pre‐ and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core‐Binding Factor Acute Myeloid Leukemia},
  journal = {European Journal of Haematology},
  year = {2025},
  doi = {10.1111/ejh.70024}
}
Kostenlos starten →